Soft Tissue Sarcoma Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals

The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Soft Tissue Sarcoma pipeline products will significantly revolutionize the Soft Tissue Sarcoma market dynamics.

DelveInsight's "Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Soft Tissue Sarcoma, historical and forecasted epidemiology as well as the Soft Tissue Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Soft Tissue Sarcoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Soft Tissue Sarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Soft Tissue Sarcoma Market Forecast
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Soft Tissue Sarcoma Market Report:
• The Soft Tissue Sarcoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In June 2025, According to results from stage 1 of the Phase 2a QB46C-H07 trial (NCT05755113), eight out of ten evaluable patients with soft tissue sarcoma treated with tigilanol tiglate (Stelfonta) experienced either complete or partial ablation of their tumors or tumor segments at any point during the study.
• In May 2025, The FDA has granted orphan drug designation (ODD) to THE001 (DPPG2-TSL-DOX), a thermosensitive liposomal formulation of doxorubicin, for treating patients with soft tissue sarcoma (STS), according to Thermosome. This follows a prior orphan drug designation by the European Medicines Agency and results from a Phase 1 trial (NCT05858710) presented at the CTOS Annual Meeting.
• In January 2025, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company specializing in targeted immunotherapeutic drugs, has announced an expansion of its Phase 1 SB101 clinical trial for SON-1010 (IL12-FHAB) in adults with advanced solid tumors. Following the successful completion of monotherapy dose escalation, the study will now include a new cohort to assess SON-1010 in combination with trabectedin (Yondelis®). This expansion aims to evaluate the immune-oncology effects of SON-1010 at the maximum tolerated dose (MTD) of 1200 ng/kg alongside trabectedin, a chemotherapy drug approved for certain advanced soft-tissue sarcomas (STS), with the goal of enhancing local immune response in the tumor microenvironment (TME).
• In October 2024, Adcendo's antibody-drug conjugate (ADC) candidate has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) and is set to advance into a Phase I/II clinical trial. The Danish immuno-oncology company will initiate the ADCElerate-01 trial, a multi-center, first-in-human Phase I/II study designed to assess the safety and efficacy of ADCE-D01 as a monotherapy in patients with metastatic and unresectable soft tissue sarcoma (STS). ADCE-D01 specifically targets the endocytic receptor uPARAP (Endo180).
• In July 2024, Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company specializing in novel immune-based intratumoral cancer therapies, has announced that the first U.S. patient has been dosed in its Phase 3 trial for metastatic sarcoma (NCT06263231). The study aims to evaluate the efficacy of INT230-6 as a monotherapy compared to the investigator's choice of three standard systemic chemotherapy options for second- or third-line treatment of metastatic, recurrent, or inoperable soft tissue sarcomas (STS). This superiority trial seeks to both directly eliminate tumors and enhance immune system recognition of cancer cells.
• In 2025, the United States is projected to see around 13,520 new soft tissue sarcoma cases, with roughly 7,600 affecting males and 5,920 affecting females, as reported by the American Cancer Society.
• The predominant types of soft tissue sarcomas in adults are undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma.
• Key Soft Tissue Sarcoma Companies: Epizyme, Blueprint Medicines, Eli Lilly, Philogen, Intensity Therapeutics, Peel Therapeutics, Pure Biologics, Edgewood Oncology, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., and others
• Key Soft Tissue Sarcoma Therapies: TAZVERIK (tazemetostat), AYVAKIT (avapritinib), LARTRUVO (olaratumab), Fibromun (L19TNF), INT230-6, PEEL-224, Selpercatinib, PBA-0405, BTX-A51, Liposomal Annamycin, and others

Soft Tissue Sarcoma Overview
Soft tissue sarcoma is a rare type of cancer that originates in the soft tissues of the body, such as muscles, fat, blood vessels, nerves, tendons, and the lining of the joints. It can occur anywhere in the body but is most common in the arms, legs, and abdomen. Symptoms may include a painless lump, swelling, or discomfort in the affected area. The exact cause is often unknown, though genetic mutations and exposure to certain chemicals or radiation can increase risk. Treatment typically involves surgery, radiation therapy, and sometimes chemotherapy, depending on the tumor type and stage. Early detection improves prognosis.

Get a Free sample for the Soft Tissue Sarcoma Market Report:
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Soft Tissue Sarcoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Soft Tissue Sarcoma Epidemiology Segmentation:
The Soft Tissue Sarcoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Soft Tissue Sarcoma
• Prevalent Cases of Soft Tissue Sarcoma by severity
• Gender-specific Prevalence of Soft Tissue Sarcoma
• Diagnosed Cases of Episodic and Chronic Soft Tissue Sarcoma

Download the report to understand which factors are driving Soft Tissue Sarcoma epidemiology trends @ Soft Tissue Sarcoma Epidemiological Insights
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Soft Tissue Sarcoma Market
The dynamics of the Soft Tissue Sarcoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2020-2034.
"The current pipeline of Soft Tissue Sarcoma is not very rich. A limited number of therapeutic approaches are being evaluated for the patients. As some molecule probably will enter in market in upcoming years, the market is supposed to experience immense growth in future"

Soft Tissue Sarcoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Soft Tissue Sarcoma market or expected to get launched during the study period. The analysis covers Soft Tissue Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Soft Tissue Sarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Soft Tissue Sarcoma Therapies and Key Companies
• TAZVERIK (tazemetostat): Epizyme
• AYVAKIT (avapritinib): Blueprint Medicines
• LARTRUVO (olaratumab): Eli Lilly
• Fibromun (L19TNF): Philogen
• INT230-6: Intensity Therapeutics
• PEEL-224: Peel Therapeutics
• Selpercatinib: Eli Lilly and Company
• PBA-0405: Pure Biologics
• BTX-A51: Edgewood Oncology
• Liposomal Annamycin: Moleculin Biotech, Inc.

To know more about Soft Tissue Sarcoma treatment, visit @ Soft Tissue Sarcoma Medications
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Soft Tissue Sarcoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Soft Tissue Sarcoma Companies: Epizyme, Blueprint Medicines, Eli Lilly, Philogen, Intensity Therapeutics, Peel Therapeutics, Pure Biologics, Edgewood Oncology, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., and others
• Key Soft Tissue Sarcoma Therapies: TAZVERIK (tazemetostat), AYVAKIT (avapritinib), LARTRUVO (olaratumab), Fibromun (L19TNF), INT230-6, PEEL-224, Selpercatinib, PBA-0405, BTX-A51, Liposomal Annamycin, and others
• Soft Tissue Sarcoma Therapeutic Assessment: Soft Tissue Sarcoma current marketed and Soft Tissue Sarcoma emerging therapies
• Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma market drivers and Soft Tissue Sarcoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Soft Tissue Sarcoma Unmet Needs, KOL's views, Analyst's views, Soft Tissue Sarcoma Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.